Literature DB >> 9520293

Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation.

J Zhan1, P Stayton, O W Press.   

Abstract

A pKK expression system in Escherichia coli was used to produce recombinant ricin A chain (rRTA) and rRTA modified by addition of organelle-specific amino acid retention sequences, including KDEL (an endoplasmic reticulum, ER, lumen retention signal), KKMP (an ER membrane retention signal), YQRL (a trans-Golgi network retention signal) and KFERQ (a lysosome-targeting signal) to the C terminus of rRTA. The toxicities of these RTA mutants were assessed in Jurkat cells following fluid-phase endocytosis. rRTA-KDEL and rRTA-YQRL were significantly more cytotoxic for Jurkat cells than rRTA, rRTA-KKMP or rRTA-KFERQ. This difference did not result from signal(KDEL or YQRL)-mediated binding of these RTA mutants to the cell surface. Reconstituted ER and Golgi vesicles have been employed to assess translocation of rRTA and mutant rRTA. RTA-KDEL and RTA-YQRL respectively exhibited 6.7-fold and 6.1-fold more protection against papain digestion in reconstituted ER vesicles and 2.2-fold and 1.8-fold more protection in reconstituted Golgi vesicles, than unmodified rRTA. These mutants were reassociated with ricin B chain to form holotoxins. The mutant RTA-KDEL and RTA-YQRL holotoxins were 3.8-fold and 1.5-fold more cytotoxic for target cells, respectively, than ricin produced using unmodified rRTA. Our results suggest that both ER and the trans-Golgi network may play important roles in the intracellular trafficking and translocation of ricin A chain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520293     DOI: 10.1007/s002620050460

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  5 in total

1.  Intracellular antibodies do not affect transport of protein toxins.

Authors:  M M Moisenovich; I I Agapov; S G Egorova; O V Tchelnokova; N V Kozlovskaia; G V Fattakhova; J Bereiter-Hahn; A G Tonevitsky
Journal:  Dokl Biochem Biophys       Date:  2001 Jul-Aug       Impact factor: 0.788

2.  Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting.

Authors:  Simon Beaudoin; Michel Paquette; Laurent Fafard-Couture; Mylene A Tremblay; Roger Lecomte; Brigitte Guérin; Jeffrey V Leyton
Journal:  J Vis Exp       Date:  2018-03-08       Impact factor: 1.355

Review 3.  Designing immunotoxins for cancer therapy.

Authors:  Christopher A Pennell; Heidi A Erickson
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 4.  How to achieve high-level expression of microbial enzymes: strategies and perspectives.

Authors:  Long Liu; Haiquan Yang; Hyun-dong Shin; Rachel R Chen; Jianghua Li; Guocheng Du; Jian Chen
Journal:  Bioengineered       Date:  2013-04-25       Impact factor: 3.269

5.  Directing ricin-based immunotoxins with targeting affibodies and KDEL signal peptide to cancer cells effectively induces apoptosis and tumor suppression.

Authors:  Seong Guk Park; Heeyeon Kim; Heejin Jun; Sun Young Choi; Eunhee Kim; Sebyung Kang
Journal:  J Nanobiotechnology       Date:  2022-08-23       Impact factor: 9.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.